Nanoform Finland Plc announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences' facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform's proprietary CESS[®] technology. Results are expected before the end of Q2/2021. The clinical trial is a progression of Nanoform's first GMP campaign. In the clinical trial, Nanoform will investigate the behavior of an oral immediate release nanoformed formulation of piroxicam, an anti-inflammatory drug. The study aims to support the potential development of fast-acting forms of piroxicam and other drugs by demonstrating the clinical utility of Nanoform's CESS[®] nanoforming[ ]technology. Nanoform's in vivo and in vitro results suggest that by significantly reducing the size of drug particles, Nanoform's CESS[®] nanoforming technology can improve the pharmacokinetic properties of piroxicam. Poor bioavailability and solubility are major causes of failure in the drug development pipeline.